Clinical trial
Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer…
NCT00307294 · University of Pittsburgh, Other · Completed
Key facts
| NCT number | NCT00307294 |
|---|---|
| Title | Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC) |
| Official title | Phase II Trial of Thalidomide and Doxil® (Doxorubicin HCL Liposome Injection) in Patients With Androgen Independent Prostate Cancer (AIPC) With a Rising PSA While on Chemotherapy |
| Lead sponsor | University of Pittsburgh, Other |
| Collaborators | Ortho Biotech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Thalidomide, Doxil |
| Enrollment | 40 |
| Start date | Mar 1, 2006 |
| Primary completion | Jan 1, 2012 |
| Completion | Jan 1, 2012 |
| First posted | Mar 27, 2006 |
| Last update posted | Nov 24, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: